AstraZeneca single dose efficacy at 90 days, rate reduction in SARS-CoV-2 infection and COVID-19 post Pfizer vaccination, super-spreaders

Peer reviewed journals featured:

- Pooled analysis of four randomised trials of AZD1222 (AstraZeneca) vaccine, including standard single dose efficacy for up to 90 days after vaccination [here](#)
- Systematic reviews on:
  - The efficacy and safety of systematic corticosteroids for COVID-19 patients [here](#)
  - The impact of COVID-19 super-spreaders [here](#)
  - Neurological manifestations associated with COVID-19 [here](#)
  - Diagnostic performance of COVID-19 serological assays during early infection [here](#)
- A randomised controlled trial of ivermectin in 62 COVID19 patients in Lagos, Nigeria [here](#)
- A modelling study on the durability of immune responses in mild-moderate COVID-19 [here](#)
- Observational studies on:
  - The outcomes of a COVID-19 recovery program for hospitalised patients in New York [here](#)
  - The effects of the pandemic on physical and mental health in the UK [here](#)
  - Harnessing peak transmission around symptom onset for COVID-19 [here](#)
  - The impact of COVID-19 in hospitals and patients in the US [here](#)
- Commentary on:
  - Vaccine prioritisation strategies in Israel and European countries [here](#)
  - Sexual orientation, race/ethnicity, and prevalence of COVID-19 comorbidities [here](#)
  - Soothing science scepticism [here](#)
  - Vaccinating low risk health care employees in the US [here](#)
  - A large scale COVID-19 vaccination program in the US [here](#)
  - The direct and indirect effects of COVID-19 [here](#)
- Editorials on:
  - Prophylactic anticoagulation for patients in hospital with COVID-19 [here](#)
  - Under-reporting of SARS-CoV-2 in Africa [here](#)
Letters and correspondence discussed:

- Concerns about a delayed second dose of the BNT162b2 (Pfizer) vaccine [here](#)
- Case reports of side effects from BNT162b2 (Pfizer) vaccine– a recurrence of Bell's Palsy [here](#) and morbilliform rash [here](#)
- Responses to Oran and Topol’s narrative review on the prevalence of asymptomatic SARS-CoV-2 infection [here](#), [here](#), [here](#), [here](#), [here](#), [here](#), and author’s reply [here](#)
- The risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults [here](#)
- Response to an article on serodiagnostics for SARS-CoV-2 [here](#) and author’s reply [here](#)
- The meaning of 95% COVID-19 vaccine efficacy [here](#)
- SARS-CoV-2 antigen rapid tests in public health responses [here](#)
- The need for a new COVID-19 social contract [here](#)
- Vaccination rates and acceptance of SARS-CoV-2 vaccination in US healthcare personnel [here](#)
- Severe relapse in an immunocompromised patient with persistent SARS-CoV-2 infection [here](#)
- Sequelae in adults at 6 months post-COVID-19 infection [here](#)
- Population subgroup differences in the use of a COVID-19 chatbot [here](#)
- The rationale to continue approving placebo-controlled COVID-19 vaccine trials [here](#)
- The risk of SARS-CoV-2 infection in patients with hypothyroidism and hyperthyroidism [here](#)
- Delayed-onset myocarditis following COVID-19 [here](#)

Pre-peer review articles featured:

- A cohort study of SARS-CoV-2 infection and COVID-19 in Pfizer vaccine recipients in Israel [here](#)
- An observational study of risk of failure in hotel quarantine in Australia and New Zealand [here](#)
- A survey-based study on changes in vaccine willingness in Australia [here](#)
- A cohort study on the duration of acute infection with B.1.1.7 variant (UK / Kent) [here](#)
- An observational study on the rise variant B.1.1.7 (UK / Kent) in the elderly in Israel [here](#)
- An evaluation on reusing N95 face mask during COVID-19 [here](#)
- An audit of CLABSI and CAUTI infections in US hospitals during the COVID-19 pandemic [here](#)

Guidance and reports

- The World Health Organization published its COVID-19 weekly epidemiological report [here](#)

Click here to subscribe to the daily evidence digest.

Emerging evidence on vaccines and variants of concern is incorporated daily into Living Evidence Tables available here

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.